Применение бета-блокаторов при ХОБЛ: мифический риск или оправданная польза?


DOI: https://dx.doi.org/10.18565/therapy.2019.5.27-35

Т.В. Адашева, Л.З. Болиева, В.В. Ли, А.Г. Малявин

1) ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова» Минздрава России 2) ФГБОУ ВО «Северо-Осетинская государственная медицинская академия» Минздрава России, г. Владикавказ
В статье анализируются результаты последних исследований, метаанализов, обосновывающие эффективность и безопасность использования бета-адреноблокаторов у пациентов с хронической обструктивной болезнью легких (ХОБЛ). Обсуждаются положительные респираторные эффекты бета-адреноблокаторов: снижение интенсивности системного воспаления, уменьшение количества обострений и госпитализаций в связи с обострением ХОБЛ. Приводятся последние экспериментальные и клиническое данные о синергичном взаимодействии бета-адреноблокаторов и бета-агонистов.
Ключевые слова: бета-адреноблокаторы, хроническая обструктивная болезнь легких, сердечно-сосудистые заболевания
Полный текст статьи доступен
в "Библиотеке Врача"

Литература


  1. Lozano R., Naghavi M., Foreman K. et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380(9859): 2095–128.

  2. Global Strategy for the Diagnosis, Management and Prevention of COPD (GOLD 2019). 2019; 155.

  3. Обрезан А.Г., Куколь Л.В., Эрднеев Б.А. Хроническая обструктивная болезнь легких и коморбидные кардиоваскулярные заболевания у лиц пожилого и старческого возраста: проблемы диагностики лечения (обзор литературы). Вестник СПбГУ. 2010; 11(2): 51–66.

  4. Авдеев С.Н., Баймаканова Г.Е. Сердечно-сосудистые заболевания у больных ХОБЛ: проблемы выбора лекарственных препаратов. Атмосфера. Пульмонология и аллергология. 2008; 2: 3–8

  5. Lahousse L., Niemeijer M.N., van den Berg M.E. et al. Chronic obstructive pulmonary disease and sudden cardiac death: the Rotterdam study. Eur Heart J. 2015; 36(27):1754–61.

  6. Sin D.D., Paul Man S.F. A curious case of b-blockers in chronic obstructive pulmonary disease. Arch Intern Med. 2010; 170: 849–50.

  7. Corrao S., Santalucia P., Argano C. et al. Gender differences in disease distribution and outcome in hospitalized elderly: data from the REPOSI study. Eur J Intern Med. 2014; 25: 617–23.

  8. de Miguel Díez J., Chancafe Morgan J., Jiménez García R. The association between COPD and heart failure risk: a review. Int J Chron Obstruct Pulmon Dis. 2013; 8: 305–12.

  9. Rothnie K.J., Yan R., Smeeth L. et al. Risk of myocardial infarction (MI) and death following MI in people with chronic obstructive pulmonary disease (COPD): a systematic review and meta-analysis. BMJ Open 2015; 5:e007824.

  10. Stefan M.S., Bannuru R.R., Lessard D. et al. The impact of COPD on management and outcomes of patients hospitalized with acute myocardial infarction: a ten-year retrospective observational study. Chest 2012; 141:1441–48.

  11. Miravitlles M., Calle M., Soler-Cataluña J.J. Clinical phenotypes of COPD: identification, definition and implications for guidelines. Arch Bronconeumol. 2012; 48: 86–98.

  12. Meyer A., Butler K., Long C. et al. Beta-blockers and COPD – inappropriate avoidance? Proceedings of Mid-South Regional Pharmacy Residents Conference. 2013; 66.

  13. Stefan M.S., Rothenberg M.B., Priva A. et al. Association between beta-blocker therapy and outcomes in patients hospitalized with acute exacerbations of chronic obstructive lung disease with underlying ischemic heart disease, heart failure or hypertension. Thorax. 2012; 67: 977–84.

  14. Государственный реестр лекарственных средств https://grls.rosminzdrav.ru/

  15. Bartels M.N., Gonzalez J.M., Kim W. et al. Oxygen supplementation and cardiac-autonomic modulation in COPD. Chest. 2000; 118(3): 691–96.

  16. Curtis B.M., O’Keefe J.H. Jr. Autonomic tone as a cardiovascular risk factor: the dangers of chronic fight or flight. Mayo Clin Proc. 2002; 77(1): 45–54.

  17. Heindl S., Lehnert M., Criée C.P. et al. Marked sympathetic activation in patients with chronic respiratory failure. Am J Respir Crit Care Med. 2001; 164(4): 597–601.

  18. Cook S., Togni M., Schaub M.C. et al. High heart rate: a cardiovascular risk factor? Eur Heart J. 2006; 27(20): 2387–93.

  19. Baker J.G., Wilcox R.G. β-Blockers, heart disease and COPD: current controversies and uncertainties Thorax. 2017; 72: 271–76.

  20. Angeloni E., Melina G., Roscitano A. et al. β-blockers improve survival of patients with chronic obstructive pulmonary disease after coronary artery bypass grafting. Ann Thorac Surg. 2013; 95: 525–31.

  21. Gottlieb S.S., McCarter R.J., Vogel R.A. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med. 1998; 339: 489–97.

  22. Mentz R.J., Wojdyla D., Fiuzat M. et al. Association of beta-blocker use and selectivity with outcomes in patients with heart failure and chronic obstructive pulmonary disease (from OPTIMIZE-HF). Am J Cardiol. 2013; 111: 582–87.

  23. Mentz R.J., Schulte P.J., Fleg J.L. et al. Clinical characteristics, response to exercise training, and outcomes in patients with heart failure and chronic obstructive pulmonary disease: findings from heart failure and a controlled trial investigating outcomes of exercise training (HFACTION). Am Heart J. 2013; 165: 193–99.

  24. Rutten F.H., Zuithoff P.A., Hak E. et al. β-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med. 2010; 170: 880–87.

  25. van Gestel Y.R., Hoeks S.E., Sin D.D. et al. Impact of cardioselective bblockers on mortality in patients with chronic obstructive pulmonary disease and atherosclerosis. Am J Respir Crit Care Med. 2008; 178: 695–700.

  26. Short P.M., Lipworth S.I., Elder D.H. et al. Effect of β blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. BMJ. 2011; 342: d2549.

  27. Etminan M., Jafari S., Carleton B. Beta-blocker use and COPD mortality: a systematic review and meta-analysis. BMC Pulm Med. 2012; 12: 48.

  28. Farland M.Z., Peters C.J., Williams J.D. et al. Beta-blocker use and incidence of chronic obstructive pulmonary disease exacerbations. Ann Pharmacother. 2013; 47: 651–56.

  29. Callaerts-Vegh Z., Evans K.L., Dudekula N. et al. Effects of acute and chronic administration of beta-adrenoceptor ligands on airway function in a murine model of asthma. Proc Natl Acad Sci USA. 2004; 101: 4948–53.

  30. Nguyen L.P., Omoluabi O., Parra S. et al. Chronic exposure to betablockers attenuates inflammation and mucin content in a murine asthma model. Am J Respir Cell Mol Biol. 2008; 38: 256–62.

  31. Egred M., Shaw S., Mohammad B. et al. Under-use of beta-blockers in patients with ischaemic heart disease and concomitant chronic obstructive pulmonary disease. Q J Med. 2005; 98: 493–97.

  32. Rasmussen D.B., Bodtger U., Lamberts M. Beta-blocker, aspirin and statin usage after first-time myocardial infarction in patients with chronic obstructive pulmonary disease: a nationwide analysis from 1995 to 2015 in Denmark. Eur Heart J Qual Care Clin Outcomes. 2019. doi: 10.1093/ehjqcco/qcy063

  33. Cargill R.I., Kiely D.G., Lipworth B.J. Adverse effects of hypoxaemia on diastolic filling in humans. Clin Sci (Lond). 1995; 89: 165–69.

  34. Kiely D.G., Cargill R.I., Grove A. et al. Abnormal myocardial repolarisation in response to hypoxaemia and fenoterol. Thorax. 1995; 50: 1062–66.

  35. Patel A.R., Donaldson G.C., Mackay A.J. et al. The impact of ischemic heart disease on symptoms, health status, and exacerbations in patients with COPD. Chest. 2012; 141: 851–57.

  36. Patel A.R., Kowlessar B.S., Donaldson G.C. et al. Cardiovascular risk, myocardial injury, and exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013; 188: 1091–99.

  37. Williams M.C., Murchison J.T., Edwards L.D. et al. Coronary artery calcification is increased in patients with COPD and associated with increased morbidity and mortality. Thorax. 2014; 69: 718–23.

  38. Chen J., Radford M.J., Wang Y. et al. Effectiveness of beta-blocker therapy after acute myocardial infarction in elderly patients with chronic obstructive pulmonary disease or asthma. J Am Coll Cardiol. 2001; 37(7): 1950–56.

  39. Andell P., Erlinge D., Smith J.G. et al. β-blocker use and mortality in COPD patients after myocardial infarction: a Swedish nationwide observational study. J Am Heart Assoc. 2015; 4: e001611.

  40. Su T-H., Chang S-H., Kuo C-F. et al. β-blockers after acute myocardial infarction in patients with chronic obstructive pulmonary disease: A nationwide population-based observational study. PLoS One. 2019; 14(3): e0213187.

  41. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2016; 37: 2129–200.

  42. Sessa M., Mascolo A., Scavone C. et al. Long-Term Clinical Impact of Beta-Blockers Selectivity to carvedilol. Frontiers in Pharmacology. 2018; 9: 1212.

  43. Hawkins N.M., Wang D., Petrie M.C. et al. Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme. Eur J Heart Fail. 2010; 12(6): 557–65.

  44. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal. 2016; 37:2893–2962.

  45. Shibata Y., Watanabe T., Osaka D. et al. Impairment of pulmonary function is an independent risk factor for atrial fibrillation: The Takahata Study. Int J Med Sci. 2011; 8(7): 514–22.

  46. Camsari A., Arikan S., Avan C. et al. Metoprolol, a β1-selective blocker, can be used safely in coronary artery disease patients with chronic obstructive pulmonary disease. Heart Vessels. 2003; 18: 188–92.

  47. Jabbour A., Macdonald P.S., Keogh A.M. et al. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. J Am Coll Cardiol. 2010; 55: 1780–87.

  48. Dungen H.D., Apostolovi С.S., Inkrot S. et al. Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial. Eur J Heart Fail. 2011; 13: 670–80.

  49. Hawkins N.M., MacDonald M.R., Petrie M.C. et al. Bisoprolol in patients with heart failure and moderate to severe chronic obstructive pulmonary disease: a randomized controlled trial. Eur J Heart Fail. 2009; 11: 684–90.

  50. Bhatt S.P., Wells J.M., Kinney G.L. et al. β-Blockers are associated with a reduction in COPD exacerbations. Thorax. 2016; 71(1): 8–14.

  51. Fuente-Maestu L., Calle M., Ortega-González A. Multicentric study on the beta-blocker use and relation with exacerbations in COPD. Respir Med. 2014; 108(5): 737–44.

  52. Wedzicha J.A., Banerji D., Chapman K.R. et al. Indacaterol-glycopyrronium versus salmeterol–fluticasone for COPD. N Engl J Med. 2016; 374: 2222–34.

  53. Calzetta L., Rogliani P., Matera M.G. et al. A systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPD. Chest. 2016; 149: 1181–96.

  54. Matera M.G., Rogliani P., Calzetta L. et al. Safety considerations with dual bronchodilator therapy in COPD: an update. Drug Saf. 2016; 39: 501–08.

  55. Oba Y., Sarva S.T., Dias S. Efficacy and safety of long-acting β-agonist/long-acting muscarinic antagonist combinations in COPD: a network meta-analysis. Thorax. 2016; 71: 15–25.

  56. Petta V., Perlikos F., Loukides S. et al. Therapeutic effects of the combination of inhaled beta2-agonists and beta-blockers in COPD patients with cardiovascular disease. Heart Fail Rev. 2017; 22(6): 753–63.

  57. Dransfield M.T., McAllister D.A., Anderson J.A. et al. β-Blocker therapy and clinical outcomes in patients with moderate chronic obstructive pulmonary disease and heightened cardiovascular risk. An Observational Substudy of SUMMIT. Ann Am Thorac Soc. 2018; 15(5): 608–14.

  58. Rinaldi B., Capuano A., Gritti G. et al. Effects of chronic administration of b-blockers on airway responsiveness in a murine model of heart failure. Pulm Pharmacol Ther. 2014; 28(2): 109–13.

  59. Rinaldi B., Donniacuo M., Sodano L. et al. Effects of chronic treatment with the new ultra-long-acting β2-adrenoceptor agonist indacaterol alone or in combination with the β1-adrenoceptor blocker metoprolol on cardiac remodelling. Br J Pharmacol. 2015; 172(14): 3627–37.

  60. Khan M., Mohsin S., Avitabile D. et al. β-Adrenergic regulation of cardiac progenitor cell death versus survival and proliferation. Circ Res. 2013; 112(3): 476–86.

  61. Rutten F.H., Hoes A.W. Chronic obstructive pulmonary disease: a slowly progressive cardiovascular disease masked by its pulmonary effects? Eur J Heart Fail. 2012; 14(4): 348–50.

  62. Lin R., Peng H., Nguyen L.P. et al. Changes in β2-adrenoceptor and other signaling proteins produced by chronic administration of β-blockers’ in a murine asthma model. Pulm Pharmacol Ther. 2008; 21(1): 115–24.

  63. Salpeter S., Ormiston T., Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005; 19(4): CD003566.

  64. Dezsi C.A., Szentes V. The real role of β-blockers in daily cardiovascular therapy. Am J Cardiovasc Drugs. 2007; 17: 361–73.

  65. Lindenfeld J., Albert N.M., Boehmer J.P.et al. Heart Failure Society of America: 2010 Comprehensive Heart Failure Practice Guidelines. J Card Fail. 2010; 16: e1–e194.

  66. Malerba M., Montuschi P., Radaeli A. et al. Role of beta-blockers in patients with COPD: current perspective. Drug Discov Today. 2015; 20: 129–35.

  67. McMurray J.J., Adamopoulos S., Anker S.D. et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J. 2012; 22: 1787–47.

  68. Yancy C.W., Jessup M., Bozkurt B. et al. 2013 ACCF/AHA Guideline for the management of heart failure. J Am Coll Cardiol. 2013; 5: S0735–S1097.


Об авторах / Для корреспонденции

Татьяна Владимировна Адашева, д.м.н., профессор кафедры поликлинической терапии ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова» Минздрава России. Адрес: 107150, Москва, ул. Лосиноостровская, д. 39, стр. 1. Тел.: 8 (499) 169-74-08. E-mail: adashtv@mail.ru
Лаура Зелимхановна Болиева, д.м.н., профессор, зав. кафедрой фармакологии с клинической фармакологией Северо-Осетинской медицинской академии, председатель правления Ассоциации аллергологов-иммунологов, пульмонологов и терапевтов РСО–Алания. Адрес: 362019, г. Владикавказ, ул. Пушкинская, д. 40. Тел.: 8 (867) 256-63-50. E-mail: bolievalz@mail.ru
Вера Валерьевна Ли, д.м.н., профессор, доцент кафедры поликлинической терапии ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова» Минздрава России. Адрес: 107150 Москва, ул. Лосиноостровская, д. 39, стр. 1. Тел.: 8 (499) 169-74-08.
Андрей Георгиевич Малявин, д.м.н., профессор кафедры фтизиатрии и пульмонологии ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова» Минздрава России, генеральный секретарь Российского научного медицинского общества, главный внештатный пульмонолог Минздрава России по ЦФО. Адрес: 127473, г. Москва, ул. Делегатская, д. 20, стр. 1. Тел.: 8 (916) 547-83-73. E-mail: maliavin@mail.ru


Похожие статьи

К содержанию номера

Бионика Медиа